Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1099
- Registration Number
- NCT00716742
A Study of 2 Doses of MAP0010 in Asthmatic Children
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 192
- Registration Number
- NCT00697697
Study of MAP0010 in Asthmatic Children and Adolescents
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 208
- Registration Number
- NCT00697801
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 70
- Registration Number
- NCT00693485
Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 278
- Registration Number
- NCT00693420
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 246
- Registration Number
- NCT00691197
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 21
- Registration Number
- NCT00661479
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 119
- Registration Number
- NCT00658619
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-05-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 279
- Registration Number
- NCT00651729
Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-05-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 62
- Registration Number
- NCT00651690
© Copyright 2024. All Rights Reserved by MedPath